EUVIMEDOpdag EUVIMED
Open access · CC BY-NC 4.0

A review of rapamycin in companion dogs

Jacob Ryave, Amanda E. Coleman

Journal of Veterinary Science · 2025 · 26 (S1) · S181

DOI: 10.4142/jvs.25219 ↗

At a glance

Journal article in Journal of Veterinary Science, 2025. Written by Jacob Ryave and 1 co-authors. Cited 2 times so far (Crossref); 109 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: National Institute on Aging.

AbstractBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Importance Aging is a complex process mediated by highly interconnected cellular, molecular and systemic pathways with genetic, environmental, dietary and lifestyle inputs, among others. Pharmacologic manipulation of aging’s molecular and cellular pathways—including those mediated by the mechanistic target of rapamycin (mTOR)—is an important ongoing area of study. Observations Inhibition of mTOR has been associated with lifespan extension and delayed or slowed age-related pathologies in several laboratory species, with cited mechanisms including improved autophagy, improved proteostasis, and reduced mRNA translation, among others. The effects of the mTOR inhibitor rapamycin on longevity in non-laboratory species is an area of emerging study, and our understanding of mTOR signaling pathways and their effects on aging continues to evolve. In people, owing to its dose-dependent immunomodulatory effects, rapamycin is currently approved as an anti-cancer agent and for prevention of organ transplant rejection or restenosis of vascular stents. Its potential use as an intervention to increase life- and healthspan in companion dogs is an area of active research. Conclusions and Relevance Rapamycin is a promising manipulator of multiple cellular and molecular hallmarks of aging. The positive results of longevity studies in laboratory species have paved the way for similar studies of rapamycin in non-human primates and companion veterinary species. The results of these and ongoing studies that evaluate the effects of mTOR inhibition for disease treatment or longevity promotion will facilitate greater understanding of the aging process and clinically meaningful ways to leverage relevant pathways.

Funding

  • National Institute on Aging

Cite

APA

Ryave, J., & Coleman, A. E. (2025). A review of rapamycin in companion dogs. Journal of Veterinary Science, 26(S1), S181. https://doi.org/10.4142/jvs.25219

Vancouver

Ryave J, Coleman AE. A review of rapamycin in companion dogs. Journal of Veterinary Science. 2025;26(S1):S181. doi:10.4142/jvs.25219

BibTeX
@article{Ryave2025,
  author = {Ryave, Jacob and Coleman, Amanda E.},
  title = {A review of rapamycin in companion dogs},
  journal = {Journal of Veterinary Science},
  year = {2025},
  volume = {26},
  number = {S1},
  pages = {S181},
  doi = {10.4142/jvs.25219}
}
Start for free →